The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The Medical journal of Malaysia

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  PMID 28733564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies

  2016cited by this paper
• Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

  2016cited by this paper
• Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis

  2015cited by this paper
• Hepatitis C virus infection: Are there still specific problems with genotype 3?

  2015cited by this paper
• Genotype 3 is the predominant hepatitis C genotype in a multi-ethnic Asian population in Malaysia.

  2015cited by this paper
• Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve ‘real-life’ patients in India

  2014cited by this paper
• Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond?

  2014cited by this paper
• Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA

  2014cited by this paper
• Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis

  2014cited by this paper
• Systematic review: Asian patients with chronic hepatitis C infection

  2013cited by this paper
• A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.

  2013cited by this paper
• Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence

  2013cited by this paper
• Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

  2012cited by this paper
• Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4

  2012cited by this paper
• Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study

  2012cited by this paper
• HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

  2011cited by this paper
• Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

  2011cited by this paper
• Liver cirrhosis in Malaysia: Peculiar epidemiology in a multiracial Asian country

  2011cited by this paper
• Outcome of sustained virological responders with histologically advanced chronic hepatitis C

  2010cited by this paper
• A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.

  2010cited by this paper
• Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

  2010cited by this paper
• Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

  2009cited by this paper
• Treatment of chronic hepatitis C in Asia: When East meets West

  2009cited by this paper
• Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.

  2009cited by this paper
• Acute hepatitis C: current status and remaining challenges.

  2008cited by this paper
• Meta‐analysis: the outcome of anti‐viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis

  2008cited by this paper
• Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

  2007cited by this paper
• Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

  2005cited by this paper
• Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case–control study

  2019cites this paper
• Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018–2040

  2018cites this paper